SC 13D/A
Beneficial Ownership Report
Eloxx Pharmaceuticals, Inc. Filed Acc 0001104659-21-070467
Stakes reported in this filing
| Reporting person | Shares | Of the class |
|---|---|---|
| Pontifax Management 4 G.P. (2015) Ltd. | 1 | 8.66% |
| Pontifax IV GP L.P. | 1 | 8.66% |
| Pontifax Management III G.P. (2011) Ltd. | 1 | 8.34% |
| Pontifax Management Fund III L.P. | 1 | 8.34% |
| Pontifax (Israel) III, L.P. | 4,900,249 | 5.69% |
| Pontifax (Israel) IV L.P. | 3,679,797 | 4.27% |
| Pontifax (Cayman) III, L.P. | 2,287,937 | 2.66% |
| Pontifax (China) IV L.P. | 1,989,551 | 2.31% |
| Pontifax (Cayman) IV L.P. | 1,791,470 | 2.08% |
| Pontifax Late Stage GP Ltd. | 616,592 | 0.72% |
| Pontifax Late Stage Fund L.P. | 616,592 | 0.72% |
Members of a group can each report the same shares, so these rows overlap and don't add up.
Stake history · largest stake in each 13D and 13G
- 2026-11-13 SCHEDULE 13G/A · Coastlands Capital LP 9.99%
- 2026-06-05 SCHEDULE 13G/A · Domicilium Capital Partners LLC 4.9%
- 2024-08-20 SC 13D/A · Advent Life Sciences LLP 3.98%
- 2023-02-13 SC 13G/A · Roche Finance Ltd 0.1%
- 2022-02-14 SC 13G/A · Roche Finance Ltd 5.8%
- 2022-02-03 SC 13D/A · LSP V Coöperatieve U.A 3.4%
- 2021-06-29 SC 13G · Gurnet Point L.P. 5.7%
- 2021-06-14 SC 13G · Roche Finance Ltd 5.3%
- 2021-05-21 SC 13D/A · Pontifax Management 4 G.P. (2015) Ltd. 8.66%
Loading tm2117123d1_sc13da.htm…